Raymond James & Associates Incyte Corp Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Incyte Corp stock. As of the latest transaction made, Raymond James & Associates holds 27,511 shares of INCY stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,511

Previous 34,790 20.92%

Holding current value

$1.97 Million

Previous $2.11 Million 13.76%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$57.33 - $68.61 $417,305 - $499,412	-7,279 Reduced 20.92%	27,511 $1.82 Million
Q2 2024 Jul 19, 2024	BUY	$51.18 - $63.75 $1.58 Million - $1.97 Million	30,852 Added 783.44%	34,790 $2.11 Million
Q1 2024 Apr 22, 2024	SELL	$56.55 - $66.59 $1.84 Million - $2.17 Million	-32,546 Reduced 89.21%	3,938 $224,000
Q4 2023 Jan 16, 2024	BUY	$52.16 - $64.19 $1.9 Million - $2.34 Million	36,484 New	36,484 $2.29 Million
Q2 2023 Jul 25, 2023	SELL	$60.95 - $75.51 $60 - $75	-1 Reduced -0.0%	20,474 $1.27 Million
Q1 2023 Apr 14, 2023	BUY	$70.23 - $86.01 $258,376 - $316,430	3,679 Added 21.9%	20,475 $1.48 Million
Q4 2022 Feb 08, 2023	SELL	$67.18 - $84.11 $92,372 - $115,651	-1,375 Reduced 7.57%	16,796 $1.35 Million
Q3 2022 Oct 25, 2022	SELL	$66.18 - $82.86 $220,048 - $275,509	-3,325 Reduced 15.47%	18,171 $1.21 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $181,465 - $228,079	2,742 Added 14.62%	21,496 $1.63 Million
Q1 2022 May 11, 2022	SELL	$66.02 - $79.71 $109,263 - $131,920	-1,655 Reduced 8.11%	18,754 $1.49 Million
Q4 2021 Feb 08, 2022	BUY	$63.34 - $74.11 $636,503 - $744,731	10,049 Added 97.0%	20,409 $1.5 Million
Q3 2021 Nov 02, 2021	SELL	$68.67 - $84.02 $516,467 - $631,914	-7,521 Reduced 42.06%	10,360 $713,000
Q2 2021 Aug 11, 2021	SELL	$79.87 - $87.53 $360,053 - $394,585	-4,508 Reduced 20.13%	17,881 $1.5 Million
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $421,911 - $557,775	-5,550 Reduced 19.86%	22,389 $1.82 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $96,968 - $117,337	1,201 Added 4.49%	27,939 $2.43 Million
Q3 2020 Nov 04, 2020	SELL	$85.07 - $109.69 $568,692 - $733,277	-6,685 Reduced 20.0%	26,738 $2.4 Million
Q2 2020 Jul 28, 2020	SELL	$74.18 - $108.93 $166,237 - $244,112	-2,241 Reduced 6.28%	33,423 $3.48 Million
Q1 2020 Apr 21, 2020	SELL	$63.18 - $85.97 $5.39 Million - $7.33 Million	-85,280 Reduced 70.51%	35,664 $2.61 Million
Q4 2019 Feb 12, 2020	SELL	$73.04 - $95.72 $6.62 Million - $8.68 Million	-90,688 Reduced 42.85%	120,944 $10.6 Million
Q3 2019 Nov 07, 2019	SELL	$72.82 - $86.52 $2.66 Million - $3.16 Million	-36,507 Reduced 14.71%	211,632 $15.7 Million
Q2 2019 Aug 06, 2019	BUY	$73.52 - $88.7 $581,763 - $701,883	7,913 Added 3.29%	248,139 $21.1 Million
Q1 2019 May 06, 2019	BUY	$63.56 - $88.17 $4.02 Million - $5.58 Million	63,324 Added 35.8%	240,226 $20.7 Million
Q4 2018 Feb 11, 2019	BUY	$58.5 - $69.94 $8.05 Million - $9.62 Million	137,607 Added 350.19%	176,902 $11.2 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $221,991 - $266,856	3,595 Added 10.07%	39,295 $2.71 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $1.73 Million - $2.39 Million	-28,443 Reduced 44.34%	35,700 $2.39 Million
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $2.92 Million - $3.55 Million	35,123 Added 121.03%	64,143 $5.35 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $335,131 - $417,661	3,582 Added 14.08%	29,020 $2.75 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $485,717 - $615,301	4,450 Added 21.2%	25,438 $2.97 Million
Q2 2017 Aug 14, 2017	BUY	N/A	20,988	20,988 $2.64 Million

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Incyte Corp Transaction History